REG - Aptamer Group PLC - Director Appointment

AptamerAnnouncement

16/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240916:nRSP2321Ea&default-theme=true

RNS Number : 2321E  Aptamer Group PLC  16 September 2024

     16 September 2024

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Director Appointment

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, announces the appointment of
Tim Sykes to its Board of Directors as a Non-Executive Director with immediate
effect.

 

Tim is an experienced executive and non-executive director, having been CEO
and, previously, CFO of Proactis Holdings PLC between 2006 and 2022 and having
served as fractional or transitionary CFO at Avacta Group plc, Altitude Group,
and Eleco plc.  Tim currently serves as Non-Executive Director at Data
Connect Group Limited and as fractional CFO at Rio AI Limited.  Tim is a
qualified chartered accountant, and at Aptamer Group he is Chair of the Audit
Committee and a member of the Remuneration Committee.

 

Dr Adam Hargreaves, Chair of the Board of Aptamer Group, commented: "As we
refocus the Group to capitalise on the Optimer assets that have been
developed, it is important that the Aptamer Board has the right commercial,
financial and operational expertise to support this. We are excited to welcome
Tim to the Board, confident that his insights will be invaluable in shaping
our capital market strategy and enhancing the financial management of the
business."

 

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, added: "With our
platform technologies gaining traction and strong performance validation
across the life sciences and healthcare sectors, we are evolving our Board to
align with the strategic needs of the company. Tim's extensive experience in
managing AIM-listed companies will be a crucial asset as we continue to grow."

 

Tim Sykes, Non-Executive Director of Aptamer Group, said: "I'm delighted to be
joining the Board of Aptamer Group at this critical time for the Company,
where the focus on strategic Optimer assets represents a potential significant
value inflection point. I look forward to collaborating with the Board and
management team at Aptamer, leveraging my experience to contribute to the
Company's strategic direction and future success."

 

Additional disclosures regarding Mr Sykes' appointment

The following details in relation to the appointment of Timothy James Sykes,
aged 54, are disclosed in accordance with Schedule 2(g) of the AIM Rules:

 

 Current directorships:               Former appointments within the past 5 years:
 Data Connect Group Limited           Proactis Holdings PLC

 Mooring Management (Filey) Limited

 

In 2018, Mr Sykes was a director of Penta Financial Direction Limited when it
was liquidated with no loss to creditors.

 

In 2017, Mr Sykes was a director of Proactis Total Procure Limited, which was
a Proactis joint venture in India, when it was compulsorily struck off having
ceased to trade.

 

 

 

- ENDS -

 

For further information, please contact:

 

 Aptamer Group plc                                            +44 (0) 1904 217 404

 Arron Tolley
 SPARK Advisory Partners Limited - Nominated Adviser          +44 (0) 20 3368 3550

 Andrew Emmott / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker               +44 (0) 20 3657 0050

 James Pope / Andrew Thacker

 

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary
Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
and research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion.

Aptamer has successfully delivered projects for a range of global pharma
companies, diagnostic development companies, and research institutes, covering
multiple application areas with the objective of establishing royalty-bearing
licenses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGZGMLLKKGDZM